Corbus reports Q2 2026 results, clears FDA hurdle for CRB-701 trial

Corbus Pharmaceuticals Holdings reported financial results and a corporate update for the second quarter of 2026 on August 6, 2026. The company obtained FDA clearance to proceed with the TEMPO-1 registrational study of 250 patients evaluating CRB-701 in second-line oropharyngeal cancer, which it said represents the first registrational trial specifically designed to evaluate a targeted treatment in this patient population.¹ Corbus expects to commence enrollment in the TEMPO-1 study in September 2026.¹

CRB-701 is a next-generation, highly stable Nectin-4 targeting antibody drug conjugate being developed to treat oropharyngeal squamous cell carcinoma and cervical cancer¹, and the FDA has granted it Fast Track designation for both cancer types.¹ The company also said it anticipates reporting CRB-701 plus Keytruda combination data in first-line oropharyngeal cancer patients in the first quarter of 2027.¹

On the obesity program, Corbus concluded last patient last visit in the CANYON-1 Phase 1b trial of CRB-913, which followed 240 patients over a 12-week treatment period plus a 4-week safety follow-up¹, and is on track to report topline data from that study in September 2026.¹

The company also announced leadership additions, including Leonardo Viana Nicacio, M.D., as Chief Medical Officer¹ and Nishant Saxena as Chief Business Officer.¹

Financially, Corbus reported a net loss of approximately $35.0 million, or $1.81 per basic and diluted share, for the quarter ended June 30, 2026, compared with a net loss of approximately $17.7 million, or $1.44 per share, a year earlier.¹ Operating expenses rose partly due to a $17.0 million increase to approximately $36.2 million, driven largely by clinical development expenses including a $10.0 million milestone payment tied to the CRB-701 license.¹ The company held $117.9 million in cash, cash equivalents, and investments as of June 30, 2026, which it expects will fund operations into 2028.¹